Effects of single dose compared with three days’ prednisolone treatment of healthy volunteers: contrasting effects on circulating lymphocyte subsets

G D Pountain, M T Keogan, B L Hazleman, D L Brown

Abstract

Aims—To investigate the effects of longer term corticosteroid treatment on circulating lymphocyte subsets.

Methods—Prednisolone (20 mg daily) was given to 12 healthy volunteers in a single morning dose for three days. Circulating lymphocyte subsets were measured by flow cytometry after whole blood lysis.

Results—Seven hours after the first dose of prednisolone there was a significant fall in absolute numbers of lymphocytes, T cells, CD4+ and CD8+ cells, and B cells. The percentage of T cells fell significantly, due to a fall in percentage of CD4+ cells. In contrast to the seven hour findings, at 72 hours there was a significant rise in absolute numbers of lymphocytes, T cells, CD4+, CD8+, and B cells. This trend was already apparent by 24 hours. The percentage of CD4+ cells was significantly raised at 72 hours, while that of CD8+ cells had fallen significantly. The percentage of natural killer cells had fallen at 72 hours; that of B cells remained increased at 72 hours.

Conclusions—These findings show that corticosteroid treatment causes significant changes in lymphocyte subsets, and that such changes must be considered when designing studies of lymphocyte subsets during illness.

(J Clin Pathol 1993;46:1089–1092)
Effects on circulating lymphocyte subsets of prednisolone EC 20 mg for three days in healthy volunteers (n = 12)

<table>
<thead>
<tr>
<th>Baseline</th>
<th>7 hours</th>
<th>24 hours</th>
<th>48 hours</th>
<th>(55 hours: n = 4)</th>
<th>72 hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lymphocytes (\times 10^9)</td>
<td>2.09</td>
<td>1.02**</td>
<td>2.53</td>
<td>2.65 (2.55)</td>
<td>3.39**</td>
</tr>
<tr>
<td>Total T cells (\times 10^9)</td>
<td>1.59</td>
<td>0.58**</td>
<td>1.84</td>
<td>2.00 (1.71)</td>
<td>2.54**</td>
</tr>
<tr>
<td>CD4+ cells (\times 10^9)</td>
<td>1.06</td>
<td>0.56**</td>
<td>1.30</td>
<td>1.42 (1.01)</td>
<td>1.61**</td>
</tr>
<tr>
<td>CD8+ cells (\times 10^9)</td>
<td>0.58</td>
<td>0.41**</td>
<td>0.67</td>
<td>0.59 (0.69)</td>
<td>0.83**</td>
</tr>
<tr>
<td>Activated T cells</td>
<td>0.11</td>
<td>0.07 NS</td>
<td>0.17</td>
<td>0.13 —</td>
<td>0.14 NS</td>
</tr>
<tr>
<td>(\times 10^11) (n = 6)</td>
<td>(p = 0.075)</td>
<td>(p = 0.063)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NK cells (\times 10^9)</td>
<td>0.32</td>
<td>0.35 NS</td>
<td>0.33</td>
<td>0.23 (0.45)</td>
<td>0.34 NS</td>
</tr>
<tr>
<td>B cells (\times 10^7)</td>
<td>0.23</td>
<td>0.15*</td>
<td>0.27</td>
<td>0.34 (0.32)</td>
<td>0.55**</td>
</tr>
<tr>
<td>T cells</td>
<td>72:5</td>
<td>61*</td>
<td>75:5</td>
<td>76 (70:5)</td>
<td>75:5 NS</td>
</tr>
<tr>
<td>(% of lymphocytes)</td>
<td>45:5</td>
<td>36*</td>
<td>48</td>
<td>49:5 (43:5)</td>
<td>51:5*</td>
</tr>
<tr>
<td>CD4+ cells (% of lymphocytes)</td>
<td>26:5</td>
<td>29 NS</td>
<td>25:5</td>
<td>24 (25:5)</td>
<td>24:5*</td>
</tr>
<tr>
<td>CD8+ cells (%)</td>
<td>4</td>
<td>6*</td>
<td>6</td>
<td>7 —</td>
<td>6 NS</td>
</tr>
<tr>
<td>Activated T cells (%)</td>
<td>16:5</td>
<td>20*</td>
<td>12:5</td>
<td>9:5 (16)</td>
<td>9:5**</td>
</tr>
<tr>
<td>Natural killer cells (%)</td>
<td>15:5</td>
<td>13*</td>
<td>12:5</td>
<td>13 (12:5)</td>
<td>14:5**</td>
</tr>
<tr>
<td>CD4+/CD8+ ratio</td>
<td>1.83</td>
<td>1.45 NS</td>
<td>2.00</td>
<td>2.10 (1.95)</td>
<td>2.10**</td>
</tr>
</tbody>
</table>

(Results expressed as medians with two tailed p values for the comparison with baseline data (Wilcoxon's rank sum test); **p < 0.01; *p < 0.05; NS = not significant.)

in the few hours after a single dose of corticosteroid has been documented in the work described above, there is little information about the effects of longer term corticosteroid administration in people, and in particular we were unable to find any study of these longer term effects in the absence of disease. We therefore studied a group of healthy volunteers taking prednisolone.

Methods

Twelve healthy volunteers were recruited from among senior medical staff. Eight were men and the ages ranged from 31 to 50 years. None had contraindications to corticosteroid administration and all gave informed consent.

A pilot study in one volunteer showed the acute postdose effects on T cell subsets to be maximal around seven hours after a dose of 20 mg prednisolone enteric coated (EC), while in the longer term maximal effects were seen after three to four days of prednisolone administration. We therefore used a three day period of corticosteroid treatment in the volunteer group with blood tests taken over four days.

Each volunteer had baseline blood samples taken at 0900 hours and then took prednisolone EC 20 mg daily orally at 0900 hours for three days. Further blood samples were taken at seven hours after the initial dose and again at 24, 48, and 72 hours—24 hours after the latest prednisolone dose, to avoid the acute postdose effects. Four volunteers also had blood samples taken at 55 hours—seven hours after the third dose of prednisolone.

All blood samples were processed within six hours of venesection. Total white cell counts and lymphocyte counts were measured using routine methods in the haematology department at Addenbrooke's Hospital. T cell subsets were analysed by flow cytometry using a whole blood lysis technique. Total T cell numbers were measured using anti-CD3 (Leu 4). Activated T cells were those CD3+ cells which coexpressed anti-HLA-DR. CD4+ cells were defined by dual staining with anti-CD3 (Leu 4) and anti-CD4 (Leu 3), while CD8+ cells were defined using anti-CD3 with anti-CD8 (Leu 2). Natural killer cells were CD3− expressing CD16/56 (Leu 11c + 19). B cells were measured using anti-CD19. All monoclonal antibodies were purchased from Becton Dickinson (Oxford, England) from the Simultest range. Aliquots of blood were incubated with antibody pairs for dual staining for 15 minutes at room temperature.
Effects of single dose compared with three days' prednisolone treatment of healthy volunteers

Erythrocytes were lysed using FACS lysing solution (Becton Dickinson) and leucocytes were fixed with 0.5% formaldehyde. Cells were analysed on the day of processing using a Becton Dickinson FACScan, and Simulset software.

The paired data for nought and seven hours and for nought and 72 hours were analysed using Wilcoxon's rank sum test.

Results
The changes in lymphocyte subsets during prednisolone treatment are shown in the table. The absolute numbers of lymphocytes, T cells, CD4+ and CD8+ and B cells had all fallen significantly by seven hours after the first dose of prednisolone, and by contrast had all risen significantly higher than baseline numbers at 72 hours (24 hours after the third dose of prednisolone) (fig 1).

As a percentage of total lymphocytes, CD4+ cells fell at seven hours, then rose significantly (table). The percentage of CD8+ cells did not change significantly at seven hours but was significantly lowered at 72 hours. This change was small. An unexpected finding was the more pronounced fall in the percentage of CD8+ cells by 72 hours in the older compared with the younger volunteers (fig 2). The Spearman rank order correlation coefficient was −0.599 (two-tailed test, p < 0.05). No correlation was seen in this study between age and the baseline percentage of CD8+ cells. No substantial difference in T cell changes was observed between men and women, but the number of women was too small for separate statistical analysis.

Values of lymphocyte subsets at 55 hours (seven hours after the third dose of prednisolone) are shown in the table, although the data were drawn from only four subjects. These values were intermediate between the seven hour and 72 hour values as might be expected, but the net effects were closer to the longer term effects—that is, the acute postdose effects are partially masked.

Discussion
This study of the effects of prednisolone on circulating lymphocyte subsets describes new findings. We have shown that the effects of continuing prednisolone administration beyond 24 hours in healthy volunteers results in effects which contrast strongly with the changes described in the first few hours after a single dose of prednisolone. These longer term effects were consistent with the changes we have observed in patients treated with prednisolone for PMR/GCA.1 Ferrari et al2 showed a similar rise in absolute numbers of lymphocytes, T cells, and CD4+ cells in patients with ITP treated with corticosteroids for four weeks, but they did not find a significant difference in the percentage of CD4+ or CD8+ cells.

Seven days of corticosteroid given to guinea pigs seem to produce different changes from those seen in studies in man. Fauci3 observed a fall in lymphocytes and T cells in guinea pigs which persisted from the acute stage to seven days. Therefore, there seems to be a species difference in the effects of long term corticosteroids on lymphocytes and subsets.

The changes we have shown seven hours after the first dose of prednisolone have confirmed the findings in the controlled studies of ten Berge et al4 and Tonnesen et al. These authors described decreased absolute numbers of lymphocytes, T cells, CD4+ and CD8+ cells a few hours after a single dose of corticosteroid. We have also shown a short term fall in the percentage of CD4+ cells.

Circadian variation in lymphocyte subsets has been shown.9,10 Ritchie et al9 described peak numbers of T cells, CD4+ and CD8+ cells at 2200 hours with an inverse correlation to plasma cortisol concentrations. Levi et al10 however, found the peak of T cells and CD4+ cells around 0200 hours, with no association with plasma cortisol values, even allowing for possible delayed hormonal action. So the role of endogenous cortisol in the diurnal changes in T cell subsets is not clear. It is perhaps not surprising that such physiological effects, if present, may be less pronounced than the pharmacological effects of corticosteroids.

In Cushing's disease absolute numbers of T cells are greatly decreased.11 This does not necessarily conflict with our finding of raised T cells numbers in volunteers and in patients with PMR/GCA patients during long term prednisolone.1 In Cushing's disease the high circulating concentration of cortisol is sustained and may be equivalent to the acute postdose effects we have seen (a fall in T cells), but persistent. In contrast to the sustained cortisol concentration in Cushing's disease, daily administration of prednisolone produces fluctuating blood concentrations, and the pre-dose samples used in our studies would contain low corticosteroid concentrations. At this stage the longer term effects of the corticosteroids would be evident, in the absence of the postdose effects.

Possible mechanisms for the changes are debatable. The acute reduction in circulating lymphocytes and T cells after a dose of prednisolone is too rapid to be attributable to an effect on lymphocyte proliferation. The
absence of fever and rigors, as seen when lymphocytes are depleted using monoclonal antibodies, suggests that cell lysis is not involved. The most likely explanation seems to be a change in lymphocyte trafficking, with sequestration in the lymphoid organs. In guinea pigs this has been shown to be due to redistribution to the bone marrow. In the longer term, the rise in circulating lymphocytes and T cells probably also reflects redistribution of the lymphocytes, but other mechanisms cannot be ruled out.

Our results suggest that the older subjects had a more pronounced fall in percentage of CD8 + cells with prednisolone, and in fact the youngest subjects actually had a slight rise in the percentage of CD8 + cells. There was no age dependent difference in baseline percentage of CD8 + cells in our study, although a decrease has been described in subjects over 60 years old and over 75 years. The numbers in our study were small and the age range was narrow (31–50 years), but if only older subjects respond to prednisolone with a decrease in the percentage of CD8 + cells, this would account for the observation of a fall in percentage of CD8 + cells in patients with PMR/GCA receiving prednisolone treatment, whose age ranged from 51–87 years (median 70 years). Ferrari et al. found no significant change in CD8 + cells in patients with ITP receiving prednisolone treatment, where the age range was 15–57 years (median 32 years). One possible mechanism for the changing responsiveness to corticosteroids with age might be the changing numbers of corticosteroid receptors. Armanini et al. have described reduced corticosteroid receptors on mononuclear leucocytes in aged subjects (62–97 years), but in vitro glucocorticoid sensitivity does not seem to be related to numbers of corticosteroid receptors. Further studies are required in volunteers and patients over a wide range of ages to clarify the T cell effects of corticosteroids in different age groups. We are now undertaking these studies.

The contrasting short term and longer term effects of corticosteroids shown in this study indicate the importance of controlling for corticosteroid effects in addition to circadian variation in all future studies of lymphocyte subsets.

We thank the volunteers for donating their time and blood, the MSL-SO of the clinical immunology laboratory for measurement of lymphocyte subsets, and Mrs Sheila Smith for typing the manuscript.

Effects of single dose compared with three days' prednisolone treatment of healthy volunteers: contrasting effects on circulating lymphocyte subsets.

G D Pountain, M T Keogan, B L Hazleman and D L Brown

doi: 10.1136/jcp.46.12.1089

Updated information and services can be found at:
[http://jcp.bmj.com/content/46/12/1089](http://jcp.bmj.com/content/46/12/1089)

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
[http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to:
[http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to:
[http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)